Depth of Response in PETHEMA/GEM Myeloma Trials Depth of Response in PETHEMA/GEM Myeloma Trials

According to this research, minimal residual disease negativity should be considered one of the most relevant clinical endpoints for some populations of patients with MM.Journal of Clinical Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news